Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
ABBV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$153.58 - $218.66
Previous CloseN/A
Volume1.02M
Average Volume (3M)7.68M
Market Cap
$330.00B
Enterprise Value$376.68B
Total Cash (Recent Filing)$41.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)78.0
Beta0.33
Next Earnings
Apr 25, 2025EPS Estimate
2.48Next Dividend Ex-Date
Apr 15, 2025Dividend Yield3.37%
Share Statistics
EPS (TTM)2.39
Shares Outstanding1,768,978,300
10 Day Avg. Volume9,018,906
30 Day Avg. Volume7,681,125
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.58
Price to Cash Flow (P/CF)13.20
P/FCF Ratio12.00
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.55
Enterprise Value/Ebitda20.75
Forecast
1Y Price Target
$214.29Price Target Upside21.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Immunology FranchiseThe strong growth algorithm for commercial powerhouses Skyrizi and Rinvoq, the two key pillars of the company's core Immunology franchise, is driving the company's topline.
Obesity Treatment StrategyAbbVie's newly established presence in the cardiometabolic/obesity space via its licensing of Gubra's long-acting amylin analogue shows potential for future growth.
Bears Say
Aesthetic Franchise ChallengesChallenging conditions are expected to continue for the Aesthetics franchise due to sluggish macro dynamics related to inflation and suppressed consumer sentiment.
Neuroscience And Oncology Pricing PressuresThe company's sizeable Neuroscience and Oncology businesses are facing some near-term pricing pressures and competition.
---
Ownership Overview
0.08% Insiders
21.64% Mutual Funds
14.77% Other Institutional Investors
41.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $153.58 and its highest was $218.66 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $330.00B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Apr 25, 2025 which is in 15 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jan 31, 2025. The company reported $2.16 earnings per share for the quarter, beating the consensus estimate of $2.115 by $0.045.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.639 which represents an annual dividend yield of 3.37%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 2.48.
How many shares outstanding does AbbVie have?
AbbVie has 1,768,978,300 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.16 in its last earnings report, beating expectations of $2.115. Following the earnings report the stock price went up 4.697%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in ABBV
---
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$214.29 (21.98% Upside)
$214.29 (21.98% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 93%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $69.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.22%
12-Months-Change
Fundamentals
Return on Equity
61.94%
Trailing 12-Months
Asset Growth
0.33%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
---
ABBV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong financial performance in 2024 with notable growth in its ex-Humira platform and advancements in neuroscience and oncology. However, challenges persist with Humira revenue erosion and the aesthetic market facing economic headwinds. Overall, the company is poised for robust growth in 2025 despite these challenges.Read More>---
ABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
---
ABBV Stock 12 Month Forecast
Average Price Target
$214.29
▲(21.98% Upside)
Technical Analysis
Best Analysts Covering ABBV
1 Year
1 Year Success Rate
37/41 ratings generated profit
1 Year Average Return
+21.93%
assigned a buy rating 2 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 90.24% of your transactions generating a profit, with an average return of +21.93% per trade.
---